Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc

Cancer Research

Volumn 68, Issue 6, 2008, Pages 1636-1646

  Ju, Tongzhong ^a   Lanneau, Grainger S ^b   Gautam, Tripti ^b   Wang, Yingchun ^a   Xia, Baoyun ^a   Stowell, Sean R ^a   Willard, Margaret T ^a   Wang, Wenyi ^a   Xia, Jonathan Y ^d   Zuna, Rosemary E ^b   Laszik, Zoltan ^b   Benbrook, Doris M ^b,c   Hanigan, Marie H ^b,c   Cummings, Richard D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d Oklahoma School of Science and Mathematics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE ANTIGEN; CHAPERONE; SIALYL TN ANTIGEN; TN ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL SURFACE; COLON CANCER; CONTROLLED STUDY; COSMC GENE; CROSS LINKING; GENE; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; SOMATIC MUTATION; UTERINE CERVIX CANCER;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GALACTOSYLTRANSFERASES; HUMANS; JURKAT CELLS; MELANOMA; MOLECULAR CHAPERONES; NEOPLASMS; TRANSFECTION; UTERINE CERVICAL NEOPLASMS;

EID: 40949133707     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2345     Document Type: Article

References (50)

1. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol 2001;491:369-402.
2. Feizi T. Carbohydrate antigens in human cancer. Cancer Surv 1985;4:245-69.
3. Xu Y, Sette A, Sidney J, Gendler SJ, Franco A. Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention. Immunol Cell Biol 2005;83:440-8.
4. Dube DH, Bertozzi CR. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov 2005;4:477-88.
5. Galonic DP, Gin DY. Chemical glycosylation in the synthesis of glycoconjugate antitumour vaccines. Nature 2007;446:1000-7.
6. Springer GF. T and Tn, general carcinoma autoantigens. Science 1984;224:1198-206.
7. Slovin SF, Keding SJ, Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol 2005;83:418-28.
8. Sewell R, Backstrom M, Dalziel M, et al. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem 2006;281:3586-94.
9. Escrevente C, Machado E, Brito C, et al. Different expression levels of α3/4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and cell lines. Int J Oncol 2006;29:557-66.
10. Serpa J, Mesquita P, Mendes N, et al. Expression of Lea in gastric cancer cell lines depends on FUT3 expression regulated by promoter methylation. Cancer Lett 2006;242:191-7.
11. Ju T, Brewer K, D'Souza A, Cummings RD, Canfield WM. Cloning and expression of human core 1 β1,3-galactosyltransferase. J Biol Chem 2002;277:178-86.
12. Ju T, Cummings RD. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 β3-galactosyltransferase. Proc Natl Acad Sci U S A 2002;99:16613-8.
13. Ju T, Cummings RD. Protein glycosylation: chaperone mutation in Tn syndrome. Nature 2005;437:1252.
14. Piller V, Piller F, Fukuda M. Biosynthesis of truncated O-glycans in the T cell line Jurkat. Localization of Oglycan initiation. J Biol Chem 1990;265:9264-71.
15. Brockhausen I, Yang J, Dickinson N, Ogata S, Itzkowitz SH. Enzymatic basis for sialyl-Tn expression in human colon cancer cells. Glycoconj J 1998;15:595-603.
16. Rye PD, Fodstad O, Emilsen E, Bryne M. Invasion potential and N-acetylgalactosamine expression in a human melanoma model. Int J Cancer 1998;75:609-14.
17. Xia L, Ju T, Westmuckett A, et al. Defective angiogenesis and fatal embryonic hemorrhage in mice lacking core 1-derived O-glycans. J Cell Biol 2004;164:451-9.
18. Avichezer D, Springer GF, Schechter B, Arnon R. Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model. Int J Cancer 1997;72:119-27.
19. Ogata S, Chen A, Itzkowitz SH. Use of model cell lines to study the biosynthesis and biological role of cancer-associated sialosyl-Tn antigen. Cancer Res 1994;54:4036-44.
20. Novogrodsky A, Lotan R, Ravid A, Sharon N. Peanut agglutinin, a new mitogen that binds to galactosyl sites exposed after neuraminidase treatment. J Immunol 1975;115:1243-8.
21. Fodstad O, Kjonniksen I, Aamdal S, Nesland JM, Boyd MR, Pihl A. Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res 1988;48:4382-8.
22. Fodstad O, Aamdal S, McMenamin M, Nesland JM, Pihl A. A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX. Int J Cancer 1988;41:442-9.
23. Kjonniksen I, Rye PD, Fodstad O. Helix pomatia agglutinin binding in human tumour cell lines: correlation with pulmonary metastases in nude mice. Br J Cancer 1994;69:1021-4.
24. Baker DA, Sugii S, Kabat EA, Ratcliffe RM, Hermentin P, Lemieux RU. Immunochemical studies on the combining sites of Forssman hapten reactive hemagglutinins from Dolichos biflorus, Helix pomatia, and Wistaria floribunda. Biochemistry 1983;22:2741-50.
25. Mitchell BS, Schumacher U. The use of the lectin Helix pomatia agglutinin (HPA) as a prognostic indicator and as a tool in cancer research. Histol Histopathol 1999;14:217-26.
26. Kawaguchi T. Cancer metastasis: characterization and identification of the behavior of metastatic tumor cells and the cell adhesion molecules, including carbohydrates. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:39-64.
27. Numa F, Tsunaga N, Michioka T, Nawata S, Ogata H, Kato H. Tissue expression of Sialyl Tn antigen in gynecologic tumors. J Obstet Gynaecol 1995;21:385-9.
28. Inoue M, Ogawa H, Nakanishi K, Tanizawa O, Karino K, Endo J. Clinical value of sialyl Tn antigen in patients with gynecologic tumors. Obstet Gynecol 1990;75:1032-6.
29. Laack E, Nikbakht H, Peters A, et al. Lectin histochemistry of resected adenocarcinoma of the lung: Helix pomatia agglutinin binding is an independent prognostic factor. Am J Pathol 2002;160:1001-8.
30. Konno A, Hoshino Y, Terashima S, Motoki R, Kawaguchi T. Carbohydrate expression profile of colorectal cancer cells is relevant to metastatic pattern and prognosis. Clin Exp Metastasis 2002;19:61-70.
31. Fernandez Madrid F, Tang N, Alansari H, Karvonen RL, Tomkiel JE. Improved approach to identify cancer-associated autoantigens. Autoimmun Rev 2005;4:230-5.
32. Kakeji Y, Tsujitani S, Mori M, Maehara Y, Sugimachi K. Helix pomatia agglutinin binding activity is a predictor of survival time for patients with gastric carcinoma. Cancer 1991;68:2438-42.
33. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
34. Chan JK, Berek JS. Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 2007;25:2975-82.
35. Miyai K, Furugen Y, Matsumoto T, et al. Loss of heterozygosity analysis in uterine cervical adenocarcinoma. Gynecol Oncol 2004;94:115-20.
36. Chow JC, Yen Z, Ziesche SM, Brown CJ. Silencing of the mammalian X chromosome. Annu Rev Genomics Hum Genet 2005;6:69-92.
37. Struewing JP, Pineda MA, Sherman ME, et al. Skewed X chromosome inactivation and early-onset breast cancer. J Med Genet 2006;43:48-53.
38. Faried A, Kimura H, Faried LS, et al. Expression of carbohydrate antigens in human esophageal squamous cell carcinoma: prognostic application and its diagnostic implications. Ann Surg Oncol 2007;14:960-7.
39. Wang PH, Lee WL, Juang CM, et al. Altered mRNA expressions of sialyltransferases in ovarian cancers. Gynecol Oncol 2005;99:631-9.
40. Julien S, Adriaenssens E, Ottenberg K, et al. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology 2006;16:54-64.
41. Vazquez-Martin C, Cuevas E, Gil-Martin E, Fernandez-Briera A. Correlation analysis between tumorassociated antigen sialyl-Tn expression and ST6GalNAc I activity in human colon adenocarcinoma. Oncology 2004;67:159-65.
42. Zhuang D, Yousefi S, Dennis JW. Tn antigen and UDP-Gal:GalNAc α-R β 1-3Galactosyltransferase expression in human breast carcinoma. Cancer Biochem Biophys 1991;12:185-98.
43. Schietinger A, Philip M, Yoshida BA, et al. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 2006;314:304-8.
44. Higashi N, Fujioka K, Denda-Nagai K, et al. The macrophage C-type lectin specific for galactose/N-acetylgalactosamine is an endocytic receptor expressed on monocyte-derived immature dendritic cells. J Biol Chem 2002;277:20686-93.
45. Saeland E, van Vliet SJ, Backstrom M, et al. The Ctype lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol Immunother 2007;56:1225-36.
46. Itzkowitz SH, Yuan M, Montgomery CK, et al. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 1989;49:197-204.
47. Ogata S, Maimonis PJ, Itzkowitz SH. Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Res 1992;52:4741-6.
48. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004;23:77-99.
49. Paszkiewicz-Gadek A, Porowska H, Lemancewicz D, Wolczynski S, Gindzienski A. The influence of Nand O-glycosylation inhibitors on the glycosylation profile of cellular membrane proteins and adhesive properties of carcinoma cell lines. Int J Mol Med 2006;17:669-74.
50. An G, Wei B, Xia B, et al. Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. J Exp Med 2007;204:1417-29.